Helpfully, the use of an intravenous insulin infusion specifically designed for pregnancy has been shown to reduce maternal hyperglycaemia in women with gestational diabetes after ACS and decrease the incidence of neonatal hypoglycaemia (29% vs. 54%) in babies receiving betamethasone within 48 hours of birth, with a number needed to treat of four33. This evidence concerns the gene INS and Hypoglycemia.